title: Radiofrequency ablation therapy combined with cementoplasty for painful bone metastases: initial experience.
abstract: The purpose of this study was to assess the efficacy and safety of percutaneous radiofrequency (RF) ablation therapy combined with cementoplasty under computed tomography and fluoroscopic guidance for painful bone metastases. Seventeen adult patients with 23 painful bone metastases underwent RF ablation therapy combined with cementoplasty during a 2-year period. The mean tumor size was 52 x 40 x 59 mm. Initial pain relief, reduction of analgesics, duration of pain relief, recurrence rate of pain, survival rate, and complications were analyzed. The technical success rate was 100%. Initial pain relief was achieved in 100% of patients (n=17). The mean VAS scores dropped from 63 to 24 (p<0.001) (n=8). Analgesic reduction was achieved in 41% (7 out of 17 patients). The mean duration of pain relief was 7.3 months (median: 6 months). Pain recurred in three patients (17.6%) from 2 weeks to 3 months. Eight patients died and 8 patients are still alive (a patient was lost to follow-up). The one-year survival rate was 40% (observation period: 1--30 months). No major complications occurred, but one patient treated with this combined therapy broke his right femur 2 days later. There was transient local pain in most cases, and a hematoma in the psoas muscle (n=1) and a hematoma at the puncture site (n=1) occurred as minor complications. Percutaneous RF ablation therapy combined with cementoplasty for painful bone metastases is effective and safe, in particular, for bulky tumors extending to extraosseous regions. A comparison with cementoplasty or RF ablation alone and their long-term efficacies is needed.
authors.affiliation: Department of Radiology, Division of Medical Intelligence and Informatics, Programs for Applied Biomedicine, Graduate School of Biomedical Science, Hiroshima University, 1-2-3, Hiroshima 734-8551, Japan. naotoyo@hiroshima-u.ac.jp
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Toyota
authors.forename: Akira
authors.initials: A
authors.lastname: Naito
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kakizawa
authors.forename: Masashi
authors.initials: M
authors.lastname: Hieda
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Hirai
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Tachikake
authors.forename: Tomoki
authors.initials: T
authors.lastname: Kimura
authors.forename: Hideki
authors.initials: H
authors.lastname: Fukuda
authors.forename: Katsuhide
authors.initials: K
authors.lastname: Ito
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001843:Bone Cements / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000000981:diagnostic imaging / Q000556:secondary* / Q000601:surgery*; D006528:Carcinoma, Hepatocellular / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000556:secondary; D017115:Catheter Ablation; D015179:Colorectal Neoplasms / Q000473:pathology; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology; D008113:Liver Neoplasms / Q000473:pathology; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019637:Orthopedic Procedures / Q000379:methods*; D010146:Pain / Q000000981:diagnostic imaging / Q000209:etiology* / Q000601:surgery; D011859:Radiography; D013964:Thyroid Neoplasms / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D001843:Bone Cements